Figure 1
From: A Phase 1 study of ARQ 087, an oral pan-FGFR inhibitor in patients with advanced solid tumours
Pharmacokinetics of ARQ 087. Mean (+s.d.) plasma concentrations of ARQ 087 vs. time after (A) a single oral dose (day 1) and (B) multiple doses (day 22) of ARQ 087 (semi-log scales).
